TRex Bio files for $100M IPO on NASDAQ under symbol TRXB

TRB-061: TRB-061 is TRex Bio's lead candidate, a TNFR2 agonist antibody in Phase 1b development for moderate-to-severe atopic dermatitis. It is designed to modulate immune responses in a tissue-specific manner. Topline data from the ongoing trial is expected in mid-2027. TRB-071: TRB-071 is a wholly-owned candidate from TRex Bio that targets CD30 for the treatment of inflammatory bowel disease. It is scheduled to enter Phase 1 clinical trials in the first half of 2027. The asset broadens the company's pipeline beyond its lead program. TRex Bio: TRex Bio is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases that aim to augment regulatory T cells in inflamed tissue to restore immune balance and repair barriers. The company applies its Deep Biology platform to map Treg function in fresh human skin, gut, and lung tissue for target identification and validation. TRex Bio filed for a $100 million IPO on the Nasdaq under the symbol TRXB, with J.P. Morgan and Evercore ISI as joint bookrunners. Eli Lilly: Eli Lilly is a global pharmaceutical company acting as both an investor in and discovery partner to TRex Bio. Through the collaboration, Eli Lilly is advancing a third candidate identified on the TRex platform into a Phase 2a trial for lupus. IPO Process: TRex Bio filed confidentially with the SEC on June 26, 2026, ahead of its public registration for the offering. Pipeline Timeline: TRex Bio expects topline data from its lead program in mid-2027 while advancing a second candidate into the clinic earlier that year.